Pharmaceutical Payments Linked to Anti-VEGF Injection Use

This article originally appeared here.
Share this content:
Pharmaceutical Payments Linked to Anti-VEGF Injection Use
Pharmaceutical Payments Linked to Anti-VEGF Injection Use

THURSDAY, June 30, 2016 (HealthDay News) -- There is a positive association between reported pharmaceutical payments and use of aflibercept and ranibizumab injections among ophthalmologists who prescribe anti-vascular endothelial growth factor (VEGF) medications, according to a study published online June 23 in JAMA Ophthalmology.

Stanford C. Taylor, M.D., from Washington University in St. Louis, and colleagues examined the correlation between reported industry payments and physician-prescribing habits for anti-VEGF injections. Data were reviewed from the Centers for Medicare & Medicaid Services (CMS) 2013 Medicare Provider Utilization and Payment Data: Physician and Other Supplier Public Use File and the CMS-sponsored August-through-December-2013 Open Payments program.

The researchers found that in 2013, 3,011 U.S. ophthalmologists were reimbursed by CMS for 2.2 million anti-VEGF injections, of whom 38 percent received $1.3 million in industry payments for ranibizumab and aflibercept. There were positive associations for increasing numbers of reported industry payments and total injection use, aflibercept and ranibizumab injection use, and the percentage of injections per physician that were aflibercept or ranibizumab. There was a smaller association between greater number of industry payments and bevacizumab injection use.

"As is inherent to the design of correlation studies, this analysis cannot determine whether the payments reported caused the increased use, are a result of the increased use, or are merely associated with some other factor that causes the increased use," the authors write.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »